Schedule 13D ownership disclosure

NovaBay Pharmaceuticals Inc

Common Stock, $0.01 par value · CUSIP: 66987P409

Event date: 2026-01-16

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Framework Ventures IV L.P.Reported CIK 0002028474

    Shares: 56,806,080.00 · Class: 45.0%

  • Framework Ventures Management LLCReported CIK 0002091751

    Shares: 56,806,080.00 · Class: 45.0%

  • Framework Ventures IV GP LLCReported CIK 0002092591

    Shares: 56,806,080.00 · Class: 45.0%

  • Spencer VanceReported CIK 0002092030

    Shares: 56,806,080.00 · Class: 45.0%

  • Anderson Michael ErnestReported CIK 0002093174

    Shares: 56,806,080.00 · Class: 45.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001437749-26-001671
Form type
SCHEDULE 13D/A
Filer
Framework Ventures IV L.P.
CIK
CIK 2028474
Filed
Jan 21, 2026
Reporting period
Jan 16, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub